Use and safety of aprotinin in routine clinical practice: A European postauthorisation safety study conducted in patients undergoing cardiac surgery
CONCLUSION
The data in the NApaR indicated that in this patient population, at high risk of death or blood loss undergoing cardiac surgery, including complex cardiac surgeries other than iCABG, the incidence of adverse events is in line with data from current literature, where aprotinin was not used.
TRIAL REGISTRATION
EU PAS register number: EUPAS11384.
Source: European Journal of Anaesthesiology - Category: Anesthesiology Tags: Cardiac surgery Source Type: research
More News: Anaphylactic Shock | Anesthesia | Anesthesiology | Bleeding | Coronary Artery Bypass Graft | Drugs & Pharmacology | European Medicines Agency (EMA) | Stroke | Study